Based on this YouTube video's total view count of 119K views and industry-standard rates, the estimated total earning is $83 - $238 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore First peer-reviewed vaccine evidence with 119,199 views, 4,603 likes, and 2,291 comments. Experience the impact of this video content that has captured audience attention.

V Day, good start Three-and-a-half, 975 doses Over-80s and NHS and care home staff 70 hospital hubs 800,000 doses One million from Belgium by next week 2020, 5 million doses Two adverse reactions Anaphylactoid Both shortly after Both fine Both history of serious allergies and carry adrenalin pens Severe allergic patents not in trials Professor Stephen Powis As is common with new vaccines, the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination after two people with a history of significant allergic reactions responded adversely Dr June Raine, (MHRA) Only right to take this step now that we've had this experience First peer-reviewed vaccine evidence Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext Oxford University Replication-deficient chimpanzee adenoviral vector Containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene. Evaluated the safety and efficacy Methods Four ongoing blinded, randomised, controlled trials UK, Brazil, and South Africa Participants aged 18 + Randomly assigned, 1:1 Vaccine or control (meningococcal group conjugate vaccine or saline) Vaccine group Two doses containing 5 × 1010 viral particles (standard dose) A subset in the UK trial, half dose first (low dose) and a standard dose second Infections recorded more than 14 days after a second dose Data cutoff Nov 4, 2020 April 23 to Nov 4, 2020 23,848 participants were enrolled 11,636 participants (7548 in the UK, 4088 in Brazil), interim primary efficacy analysis There were 131 cases of symptomatic COVID-19 in LD/SD or SD/SD recipients combined Vaccine group N = 5,807 30 cases Control group N = 5,829 101 cases Resulting in overall vaccine efficacy of 70.4% SD/SD group Vaccine group, 27 cases Control group, 71 cases Vaccine efficacy was 62·1% UK, 60·3% efficacy Brazil, 64·2% efficacy LD/SD goup Vaccine group, 3 cases from 1,367 Control group 30 cases from 1,374 Vaccine efficacy was 90% LD/HD group had less asymptomatic infections Six week gap may also help Implications for ongoing contagion From 21 days after the first dose Ten cases hospitalised for COVID-19, two classified as severe, one death Vaccine efficacy 100% Safety 74,341 person-months of safety follow-up 175 severe adverse events occurred in 168 participants 84 events in vaccine group 91 in the control group Three events were classified as possibly related to a vaccine One in the vaccine group, one in the control group

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.